These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35709539)

  • 1. A retrospective review of implementation of an inhaled epoprostenol protocol in the emergency department.
    Toomey D; O'Brien M; Hayes BD; Wilcox S
    Am J Emerg Med; 2022 Aug; 58():210-214. PubMed ID: 35709539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Economic Impact of Formulary Conversion From Inhaled Flolan to Inhaled Veletri for Refractory Hypoxemia in Critically Ill Patients.
    Torbic H; Szumita PM; Anger KE; Nuccio P; Lagambina S; Weinhouse G
    Ann Pharmacother; 2016 Feb; 50(2):106-12. PubMed ID: 26668204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery.
    De Wet CJ; Affleck DG; Jacobsohn E; Avidan MS; Tymkew H; Hill LL; Zanaboni PB; Moazami N; Smith JR
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1058-67. PubMed ID: 15052203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness, Safety, and Economic Comparison of Inhaled Epoprostenol Brands, Flolan and Veletri, in Acute Respiratory Distress Syndrome.
    Hawn JM; Bauer SR; Wanek MR; Li M; Wang X; Duggal A; Torbic H
    Ann Pharmacother; 2020 May; 54(5):434-441. PubMed ID: 31729256
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of the Efficacy and Safety of Inhaled Epoprostenol and Inhaled Nitric Oxide for Refractory Hypoxemia in Patients With Coronavirus Disease 2019.
    DeGrado JR; Szumita PM; Schuler BR; Dube KM; Lenox J; Kim EY; Weinhouse GL; Massaro AF
    Crit Care Explor; 2020 Oct; 2(10):e0259. PubMed ID: 33134949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpected Interruptions in the Inhaled Epoprostenol Delivery System: Incidence of Adverse Sequelae and Therapeutic Consequences in Critically Ill Patients.
    Block JM; Madhok J; Owyang CG; Merriman KR; Ruoss SJ; Rao VK
    Crit Care Explor; 2021 Oct; 3(10):e0548. PubMed ID: 34671745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninferiority of Inhaled Epoprostenol to Inhaled Nitric Oxide for the Treatment of ARDS.
    Ammar MA; Bauer SR; Bass SN; Sasidhar M; Mullin R; Lam SW
    Ann Pharmacother; 2015 Oct; 49(10):1105-12. PubMed ID: 26187741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19.
    Sonti R; Pike CW; Cobb N
    J Intensive Care Med; 2021 Mar; 36(3):327-333. PubMed ID: 33234007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults.
    Buckley MS; Feldman JP
    Pharmacotherapy; 2010 Jul; 30(7):728-40. PubMed ID: 20575636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients.
    Torbic H; Szumita PM; Anger KE; Nuccio P; LaGambina S; Weinhouse G
    J Crit Care; 2013 Oct; 28(5):844-8. PubMed ID: 23683572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness, safety, and Economic Comparison of Two Inhaled Epoprostentol Products (Flolan and Veletri) in Cardiothoracic Surgery Patients.
    Hawn JM; Wanek M; Bauer SR; Ammar MA; Insler S; Adi A; Torbic H
    Ann Pharmacother; 2018 Oct; 52(10):956-964. PubMed ID: 29749260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitric oxide versus epoprostenol for refractory hypoxemia in Covid-19.
    Poonam PBH; Koscik R; Nguyen T; Rikhi S; Lin HM
    PLoS One; 2022; 17(6):e0270646. PubMed ID: 35759496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled Epoprostenol Through Noninvasive Routes of Ventilator Support Systems.
    Ammar MA; Sasidhar M; Lam SW
    Ann Pharmacother; 2018 Dec; 52(12):1173-1181. PubMed ID: 29890848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of Converting Inhaled Epoprostenol Product From Flolan to Veletri in Critically Ill Patients.
    Torbic H; Bauer SR; Wanek MR
    Am J Ther; 2020 Oct; 28(6):e781-e785. PubMed ID: 33021539
    [No Abstract]   [Full Text] [Related]  

  • 15. Use and costs of inhaled nitric oxide and inhaled epoprostenol in adult critically ill patients: A quality improvement project.
    Davis SL; Crow JR; Fan JR; Mattare K; Whitman G; Brower RG; Rowden A; Pustavoitau A
    Am J Health Syst Pharm; 2019 Sep; 76(18):1413-1419. PubMed ID: 31372630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit.
    Haché M; Denault AY; Bélisle S; Couture P; Babin D; Tétrault F; Guimond JG
    Can J Anaesth; 2001 Oct; 48(9):924-9. PubMed ID: 11606352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of Nurse-Managed Inhaled Nitric Oxide During Critical Care Interfacility Transport.
    Troncoso R; Garfinkel EM; Kaul K; Leon D; Trautman S; Margolis AM
    J Intensive Care Med; 2023 Aug; 38(8):768-772. PubMed ID: 37229698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled epoprostenol to support the severely hypoxemic patient with acute respiratory distress syndrome.
    Arumpanayil A
    Dimens Crit Care Nurs; 2013; 32(5):229-36. PubMed ID: 23933641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary Vasodilator Response of Combined Inhaled Epoprostenol and Inhaled Milrinone in Cardiac Surgical Patients.
    Elmi-Sarabi M; Jarry S; Couture EJ; Haddad F; Cogan J; Sweatt AJ; Rousseau-Saine N; Beaubien-Souligny W; Fortier A; Denault AY
    Anesth Analg; 2023 Feb; 136(2):282-294. PubMed ID: 36121254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of early inhaled epoprostenol therapy on pulmonary artery pressure and blood loss during LVAD placement.
    Groves DS; Blum FE; Huffmyer JL; Kennedy JL; Ahmad HB; Durieux ME; Kern JA
    J Cardiothorac Vasc Anesth; 2014 Jun; 28(3):652-60. PubMed ID: 24103713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.